ResMed Inc. reports developments in sleep health, respiratory care and home healthcare technology. The company supplies sleep apnea and breathing-care devices, including CPAP platforms such as AirSense 11, and supports them with cloud-connected software, AI-enabled digital health tools and patient data applications used in out-of-hospital care.
Recurring updates include quarterly operating results, demand trends for sleep and respiratory care products, FDA-cleared digital medical devices such as Smart Comfort, supply-chain and distribution capacity, shareholder returns, executive leadership changes and investor conference presentations. ResMed’s announcements also reflect its NYSE-listed common stock and ASX-traded presence.
Resmed (NYSE: RMD) announced that CFO Brett Sandercock will retire effective May 4, 2026, and Aaron Bloomer will succeed him as CFO. Sandercock will advise the CEO through end of 2027. The company reiterated fiscal 2026 outlook: gross margin 62–63%, SG&A 19–20%, R&D 6–7%, effective tax rate 21–23%.
Resmed (NYSE: RMD) reported Q3 FY2026 results for the quarter ended March 31, 2026: revenue $1.431B (up 11% reported, 8% constant currency), GAAP gross margin 62.2% (+290 bps), GAAP diluted EPS $2.74 and non-GAAP diluted EPS $2.86 (+21%).
Operating cash flow was $554M; the company returned $262M to shareholders via $175M buybacks and $87M dividends, and declared a quarterly dividend of $0.60 per share.
Resmed (NYSE: RMD) will report third quarter fiscal 2026 results on Thursday, April 30, 2026 after the NYSE close and will host a management webcast at 1:30 p.m. PT / 4:30 p.m. ET.
The live webcast is available at https://investor.resmed.com, with replay accessible about two hours after the presentation; phone replay runs April 30–May 14, 2026.
Resmed (NYSE: RMD) released its 2026 Global Sleep Survey of 30,000 people across 13 countries, finding strong awareness but limited action on sleep health.
Key findings: 53% rank sleep the top health behavior, 84% link sleep to longevity, wearable sleep tracking rose to 53%, yet only 23% sought medical help for ongoing issues despite 66% saying they would.
Resmed (NYSE: RMD) will open a new distribution center in Greenwood, Indiana, scheduled to begin operations in 2027. The facility is expected to employ more than 100 full-time and contingent workers and will complement centers in Atlanta and Moreno Valley.
The Greenwood hub will raise two-day transit coverage across North America from 75% to 90% and shorten deliveries to Canada by one day, strengthening U.S. distribution capacity and local job creation.
Resmed (NYSE: RMD) reported Q2 FY2026 results for the quarter ended December 31, 2025: revenue $1.423B (+11% YoY; +9% constant currency), gross margin 61.8% (+320 bps), GAAP diluted EPS $2.68 and non-GAAP diluted EPS $2.81 (+16% non-GAAP). Operating cash flow was $340M. The company paid in dividends, repurchased 704,000 shares for $175M, and declared a quarterly dividend of $0.60 per share.
Management cited manufacturing and logistics efficiencies, component cost improvements, and ongoing investment in digital health and the VirtuOx acquisition as drivers of performance.
Resmed (NYSE: RMD) will report second quarter fiscal 2026 financial and operational results on Thursday, January 29, 2026 after NYSE close. Management will host a live webcast discussing results and other forward-looking material at 1:30 p.m. PST / 4:30 p.m. EST (International: London 9:30 p.m. GMT; Sydney Jan 30 8:30 a.m. AEDT).
The webcast is available only at https://investor.resmed.com. A replay will be posted ~two hours after the webcast; a phone replay is available ~three hours after the webcast through February 12, 2026 (Conference ID: 13757750).
Resmed (NYSE: RMD) announced that Mick Farrell, chairman and chief executive officer, and Dr. Carlos Nunez, chief medical officer, will present at the 44th Annual J.P. Morgan Healthcare Conference on Monday, January 12, 2026 at approximately 10:30 a.m. PST in San Francisco.
The company said a live, audio-only webcast will be available via the investor website investor.resmed.com. An audio replay will be posted about 24 hours after the live event and remain accessible for 30 days.
Resmed (NYSE: RMD) received FDA clearance on December 8, 2025 for Personalized Therapy Comfort Settings, marketed as Smart Comfort, an AI-enabled digital medical device that recommends individualized CPAP comfort settings. Smart Comfort uses machine learning trained on more than 100 million nights of de-identified sleep data to adjust pressure ramp, exhale pressure relief and easing-into-therapy settings. A limited U.S. beta for new myAir users paired with AirSense 11 will launch in early 2026, followed by a broader U.S. rollout later in 2026. The feature provides non-prescription comfort recommendations and aims to improve engagement and sustained adherence without changing prescribed therapy settings.
Resmed (NYSE: RMD) reported fiscal Q1 2026 results for the quarter ended September 30, 2025, with revenue $1.336B (up 9% year‑over‑year; +8% constant currency) and gross margin 61.5% (up 290 bps).
Non‑GAAP gross margin rose 280 bps to 62.0%. Income from operations was $446.5M (+15%); non‑GAAP income from operations was $482.1M (+19%). Net income was $348.5M and diluted EPS was $2.37 (non‑GAAP EPS $2.55, +16%). Operating cash flow was $457M. The board declared a quarterly cash dividend of $0.60 per share and repurchased 523,000 shares for $150M.